Skip to Main content Skip to Navigation
Journal articles

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL

Abstract : Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these mutations or any other, alone or in combination, remains unclear at relapse. The genome of 114 relapsed/refractory patients included in prospective trials was screened using targeted next-generation sequencing of the TP53, SF3B1, ATM, NOTCH1, XPO1, SAMHD1, MED12, BIRC3, and MYD88 genes. We performed clustering according to both number and combinations of recurrent gene mutations. The number of genes affected by mutation was ≥2, 1, and 0 in 43 (38%), 49 (43%), and 22 (19%) respectively. Recurrent combinations of ≥2 mutations of TP53, SF3B1, and ATM were found in 22 (19%) patients. This multiple-hit profile was associated with a median progression-free survival of 12 months compared with 22.5 months in the remaining patients (P = .003). Concurrent gene mutations are frequent in patients with relapsed/refractory CLL and are associated with worse outcome
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01263113
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, January 27, 2016 - 1:55:17 PM
Last modification on : Friday, March 27, 2020 - 2:52:16 AM

Links full text

Identifiers

Citation

Romain Guièze, Pauline Robbe, Ruth Clifford, Sophie Guibert, Bruno Pereira, et al.. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood, American Society of Hematology, 2015, 126 (18), pp.2110--2117. ⟨10.1182/blood-2015-05-647578⟩. ⟨hal-01263113⟩

Share

Metrics

Record views

319